Latest Conference Articles

September 6th 2023, 9:06pm

Society of Hematologic Oncology Annual Meeting (SOHO)

The addition of the TKI ponatinib to reduced-intensity chemotherapy led to an increase in minimal residual disease-negative complete remission rate at the end of induction compared with imatinib among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

September 6th 2023, 8:54pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Varying outcomes were observed among adolescent and young adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia who were treated with pediatric-inspired protocols vs adult chemotherapy regimens.

September 6th 2023, 7:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

The safety profiles and the high response rates observed with bispecific antibodies in patients with B-cell lymphoma suggest that these agents possess the potential to revolutionize the management of these diseases, particularly follicular lymphoma.

September 5th 2023, 8:43pm

Ravi Salgia, MD, PhD, discusses clinical gaps in the development of novel targets in lung cancer that were discussed at the 2023 Bridging the Gaps in Lung Cancer meeting, as well as potential strategies or steps to address these gaps in clinical practice.

August 22nd 2023, 7:00pm

Barbara Pistilli, MD, discusses the mechanism of action of novel ADCs, the ways in which ADC targets in breast cancer can change over time, and how future research may pave the way for individualized treatment with this class of agents.

August 16th 2023, 8:40pm

Bridging the Gaps in Lung Cancer

Erminia Massarelli, MD, PhD, MS, discusses unmet needs in the treatment of patients with small cell lung cancer that were discussed at the 2023 Bridging the Gaps in Lung Cancer meeting, as well as how further research may help mitigate these needs.

August 16th 2023, 7:10pm

The natural killer T-cell agonist IMM60 may overcome resistance to PD-1 inhibitors when combined with immunotherapy in patients with melanoma and non–small cell lung cancer.

August 15th 2023, 8:00pm

European Hematology Association Congress

Harry Gill, MD, discusses the importance of offering patients with APL an entirely oral treatment regimen, key efficacy findings from this trial, and the tolerability of this regimen.

August 7th 2023, 4:00pm

Tony S.K. Mok, MD, BMSc, FRCPC, FASCO, provides perspective on the use of tumor treating fields in lung cancer, the use of anti–PD-L1 inhibitors approved in China, and the potential impact of the microbiome on response with immunotherapy.

August 3rd 2023, 4:49pm

Bridging the Gaps in Lung Cancer

Edward S. Kim, MD, MBA, discusses the importance of the Bridging the Gaps in Lung Cancer meeting, and expands on the importance of educating clinicians on how to best implement new developments within lung cancer to address these gaps in care.

August 2nd 2023, 9:15pm

Solange Peters, MD, PhD, discusses the successes and shortcomings of immunotherapy in patients with lung cancer; current challenges with defining resistance mechanisms to immunotherapy in this disease; and the potential applications of circulating tumor DNA monitoring in the early and metastatic disease settings.

August 1st 2023, 1:00pm

Alex Herrera, MD, discussed key data from the SWOG S1826 trial and other important research in hematologic malignancies presented at the 2023 ASCO Annual Meeting.

July 29th 2023, 11:34pm

International Lung Cancer Congress

Tony S.K. Mok, MD, BMSc, FRCPC, FASCO, highlights novel partners and potential new approaches for immunotherapy-based regimens for the treatment of patients with non–small cell lung cancer.

July 29th 2023, 11:28pm

International Lung Cancer Congress

Antibody-drug conjugates represent one of the most exciting areas of ongoing development for the treatment of patients with non–small cell lung cancer and small cell lung cancer.

July 29th 2023, 4:29pm

International Lung Cancer Congress

Lyudmila A. Bazhenova, MD, discusses potential combination strategies with KRAS G12C inhibitors in advanced non–small cell lung cancer.

July 29th 2023, 3:16pm

International Lung Cancer Congress

Deborah B. Doroshow, MD, PhD, discusses the efficacy and toxicity profiles of pralsetinib and selpercatinib and how they influence treatment selection for patients with RET fusion–positive non–small cell lung cancer, and provides insight on several areas of ongoing or potential research in lung cancer.

July 29th 2023, 12:44am

International Lung Cancer Congress

Hatim Husain, MD, discusses developments in ALK-positive non–small cell lung cancer.

July 29th 2023, 12:27am

International Lung Cancer Congress

Edgardo Santos, MD, FACP, FCCP, discusses testing and treatment in NRG1 fusion–positive non–small cell lung cancer.

July 28th 2023, 8:47pm

International Lung Cancer Congress

Edward S. Kim, MD, MBA, discusses necessary changes that would make cancer research more accessible to patients in community settings, multidisciplinary efforts that should take place at every step of the trial design and implementation process, and how future clinical trials should be intentional about the patient demographics.

July 28th 2023, 7:45pm

International Lung Cancer Congress

Immunotherapy administered alone or in combination with chemotherapy has become the standard of care across advanced non–small cell lung cancer in several settings, with continued effort devoted to further enhancing and improving upon these treatments.